|
Match
|
Document |
Document Title |
|
|
7605151 |
Nitrate esters of corticoid compounds and pharmaceutical applications thereof
Compounds of the formula
and use of the compounds as medicaments.
|
|
|
7597914 |
Ala-septic pre-cancerous liquid dissolving solution and method
Alcohol constitutes a majority of the solution. Water, melaleuca alternifolia, amebicidal, acetate, aloe barbadensis, larrea tridentat and benzoic acid constitute a minority of the solution. The...
|
|
|
7579335 |
Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
The present invention is directed to compounds of formula (I):
wherein
R 1 represents C 4 -C 7 branched alkyl group, a bicycloalkyl group, or a C 5 -C 6 cycloalkyl which optionally may be...
|
|
|
7550451 |
Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy
The invention relates to new compounds of general formula I,
their production and pharmaceutical preparations that contain these compounds.
The compounds according to the invention are...
|
|
|
7538100 |
17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
The invention relates to 17α-alkyl-17β-oxy-estra-1,3,5(10)-trienes that have an antiestrogenic action with general formula I. In addition, the invention also relates to...
|
|
|
7538099 |
Antiprogestin method and kit for reducing side effects associated with low dosage HRT, oral contraception and regulating menses
Menses regulation and, when desired, contraception is achieved at low doses of estrogen and progestin, which otherwise would create episodes of breakthrough bleeding and/or withdrawal amenorrhea,...
|
|
|
7528123 |
Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11β-substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it...
|
|
|
7521439 |
Glucocorticoid receptor ligands for the treatment of metabolic disorders
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the...
|
|
|
7514420 |
Steroids having 1,8-unsaturation and formulations comprising same
The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in...
|
|
|
7482334 |
Therapeutic treatment methods
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include...
|
|
|
7468362 |
Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists
Compositions containing β 2 adrenergic agonists in combination with carbonates and carbonates of the formula
and in combination with related steroid carbonates and carbonates are disclosed....
|
|
|
7435757 |
2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I
in which
R 2 means a C 1 -C 8 -alkyl group, a C 1 -C 8 -alkyloxy group or a halogen atom,...
|
|
|
7419971 |
Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17α-alkoxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate type...
|
|
|
7410959 |
Therapeutic uses for aminosterol compounds
A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically...
|
|
|
7402578 |
Methods for inhibiting cognitive deterioration in adults with down's syndrome
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can...
|
|
|
7390796 |
Fatty acid modified forms of glucocorticoids
Compounds are disclosed of the formula
in which R 3 is C 8 to C 24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by...
|
|
|
7378404 |
8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
This invention describes the new 8β-substituted estratrienes of general formula I in which R 2 , R 3 , R 6 , R 6′ , R 7 , R 7′ , R 9 , R 11 , R 11′ , R 12 , R 14 , R 15 , R 15′ , R 16 , R...
|
|
|
7374747 |
Pharmaceutical foam
The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising...
|
|
|
7361646 |
Methods for treating gastroesophageal reflux disease
This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in...
|
|
|
7326697 |
Methods for increasing the therapeutic response to electroconvulsive therapy
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to the glucocorticoid...
|
|
|
7323454 |
Etonogestrel esters
The subject invention provides new progestogen esters and uses thereof.
|
|
|
7291609 |
Specific glucocorticosteroid compound having anti-inflammatory activity
A compound of formula (I):
or a physiologically acceptable solvate thereof.
|
|
|
7291608 |
Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
There are provided compounds of formula (I)
wherein the variables are as defined by the present specification; and solvates thereof, processes for preparing them and their use in therapy.
|
|
|
7279467 |
Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors
The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In...
|
|
|
7259180 |
Methods and compositions for treatment of macular and retinal disease
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for...
|
|
|
7253155 |
Combinations for the treatment of immunoinflammatory disorders
The invention features a method for treating a patient having an immunoinflammatory disorder, by administering to the patient (i) a tetra-substituted pyrimidopyrimidine, and (ii) a corticosteroid...
|
|
|
7250408 |
Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
The novel glucocorticoid receptor antagonists are 11β-substituted steroid compounds of formula (I):
wherein R 1 denotes a methyl group, a methoxy group, or an ethoxy group; wherein R 2 ...
|
|
|
RE39678 |
Meiosis regulating compounds
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
|
7208485 |
Crystalline forms of halobetasol propionate
The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction...
|
|
|
7196074 |
Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
Methods of using 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one (III)
and 17 esters thereof for various hormonal therapies, oral and parenteral dosage forms comprising these actives, and...
|
|
|
7192942 |
Process for production of crystals of 11μ-benzaldoxim-estra-4,9-diene derivatives, crystals obtained thereby and pharmaceutical preparations containing them
The process for making crystals of a 11 β-benzaldoxim-estra-4,9-diene derivative having an average particle size of from 3 μm to 25 μm and a maximum particle size of 100 μm, includes subjecting...
|
|
|
7189761 |
Nitric oxide donor composition and method for treatment of anal disorders
A pharmaceutical composition contains a nitric oxide donor and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders...
|
|
|
7189703 |
Treatment and diagnosis of alzheimer's disease
The invention relates to a method of treating Alzheimer's disease in a mammal comprising administering to the mammal an anti-microbial agent having anti- Chlamydia pneumoniae activity. The...
|
|
|
7186708 |
Steroidal compounds
Steroidal compounds or their salts having general formula:
A—B—C—NO 2
...
|
|
|
7182956 |
Stable topical drug delivery compositions
A stable composition of a drug comprising a carrier having a phosphatidylcholine component which entraps the drug is applied to the skin for transdermal delivery of the drug.
|
|
|
7163934 |
Methods for treating delirium glucocorticoid receptor-specific antagonists
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used...
|
|
|
7157450 |
Nitrate esters of corticoid compounds and pharmaceutical applications thereof
Compounds of the formula
and use of the compounds as medicaments.
|
|
|
7157097 |
Penetration enhancing and irritation reducing systems
This invention lies in the technology of transdermal and topical drug delivery. In particular, the present invention relates to enhancement of the penetration of transdermally or topically applied...
|
|
|
7148213 |
Antigestagenically active steroids with a fluorinated 17α-alkyl chain
This invention describes the new 17α-fluoroalkyl steroids of general formula I
as well as their physiologically compatible salts with bases.
The new compounds have an extraordinary strong...
|
|
|
7148212 |
Process for production of steroid crystals, steroid crystals obtained thereby and pharmaceutical preparations containing them
The process for making steroid crystals having a predetermined average particle size of from 1 μm to 25 μm and a maximum particle size that does not exceed a predetermined maximum value of 100...
|
|
|
RE39264 |
Pharmaceutical combination
The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically...
|
|
|
7087591 |
21-substituted progesterone derivatives as new antiprogestational agents
A compound having the general formula:
in which: R 1 is a member selected from the group consisting of —OCH 3 , —SCH 3 , —N(CH 3 ) 2 , —NHCH 3 , —CHO, —COCH 3 and —CHOHCH 3 ; R...
|
|
|
7034060 |
Polycosanols from Ericerus pela wax
The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela...
|
|
|
7030132 |
Method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
A method for increasing the systemic exposure of cells selected from tumor cells and normal cells to an orally administered pharmaceutically active compound, wherein a bioenhancer comprising an...
|
|
|
7022687 |
Combination of loteprednol and antihistamines
The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and/or levocabastine, for...
|
|
|
7018993 |
Antiandrogenic agent
A compound pf general formula (I):
wherein, for example,
X 1 and X 2 independently represent a hydrogen atom. R a represents a hydrogen atom or a protecting group for a hydroxyl...
|
|
|
6995150 |
Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions...
|
|
|
6995149 |
Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
The present invention relates to a female mammal contraceptive process consisting of the sequential administration for at least 28 days of (a) a gestagen in an ovulation-preventing dose for at...
|
|
|
6992075 |
C(14) estrogenic compounds
The present invention relates to novel estrogenic compounds. The present invention also relates to methods of treating estrogen deprivation in a subject comprising administering novel estrogenic...
|
|
|
6977250 |
Prevention of ovarian cancer by administration of progestin products
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as...
|